Erlotinib Completed Phase 1 Trials for Cancer, Breast / Estrogen Receptor Breast Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00456833Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy
NCT00444015Phase I Dasatinib/Erlotinib in Recurrent Non-small Cell Lung Cancer (NSCLC)
NCT01199068CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)
NCT00581789Erlotinib and Sunitinib in NSCLC
NCT00294736A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens
NCT01545947Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
NCT01069757A Study of ARQ 197 in Combination With Erlotinib
NCT00702182Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
NCT00574366Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer
NCT01594398Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
NCT01650506Study of Erlotinib and Metformin in Triple Negative Breast Cancer
NCT00965731Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
NCT02507375A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00072072Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer